Galapagos reported promising results from ATALANTA-1 study show 100% ORR/CR for relapsed Mantle Cell Lymphoma. Click for GLPG ...

The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105.

China’s NMPA has approved InnoCare Pharma’s orelabrutinib for use as a first-line treatment for CLL and small lymphocytic ...

Today’s recommendation is an important advance within the mantle cell lymphoma first-line treatment landscape, especially for older patients who need a balance of efficacy and tolerability.” Susan ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced today that its BTK inhibitor orelabrutinib received approval from the China National Medical Products ...

clonoSEQ is now covered to monitor for recurrence in MCL patients who are in treatment-free remission SEATTLE ... to monitor for recurrence in patients with a history of mantle cell lymphoma (MCL).

China NMPA approves InnoCare Pharma’s orelabrutinib for first-line treatment of patients with CLL/SLL: Beijing Monday, April 28, 2025, 12:00 Hrs [IST] InnoCare Pharma, a leading ...

Under the expanded coverage decision, patients who have completed treatment are now covered ... MCL is a sub-type of non-Hodgkin lymphoma (NHL) with an annual incidence of approximately 4,000 ...